Pustular Psoriasis

Patients with generalized pustular psoriasis continued to experience frequent flares that were often uncontrolled by traditional off-label therapies, according to a study.

As the year comes to a close, Healio Dermatology has assembled this year’s top psoriasis articles. 

The FDA has approved an expanded indication for Spevigo injection to treat generalized pustular psoriasis in pediatric patients aged 12 years and older weighing 40 kg or more, Boehringer Ingelheim announced in a press release.

The phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab for the treatment of patients with generalized pustular psoriasis flares met its primary endpoint, AnaptysBio announced in a press release.

Spevigo significantly outperformed placebo in reducing the risk for generalized pustular psoriasis flares, Boehringer Ingelheim announced in a press release after its late-breaker session at the 25th World Congress of Dermatology.

In this video, Tracey Henslee, CRNP, discusses the treatment of pustular psoriasis, a highlight of this year’s Fall Clinical Dermatology Conference for PAs & NPs held in Orlando.

Three-quarters of patients with generalized pustular psoriasis demonstrated response to treatment with an interleukin-36-targeted therapy as early as 4 weeks, according to a study.

Spesolimab exhibited rapid control of generalized pustular psoriasis flare symptoms in as little as 24 hours and up to 12 weeks, according to a study.